AdvanCell is a Biotech company based in Brisbane, Australia. It has raised $440M in total funding. Latest round: Series D.
AdvanCell funding overview
AdvanCell is a Biotech company based in Brisbane, Australia. AdvanCell has raised $440M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in January 2026. The round record for AdvanCell runs through 2026; nothing later has been disclosed. Investors on record include Ally Bridge Group, Alpha Wave, Bain Capital Life Sciences, Fidelity Management & Research, T. Rowe Price, Qatar Investment Authority and 8 others. 14 distinct backers are named across the disclosed rounds.
AdvanCell at a glance
Total raised
$440M
Latest round
Series D
Latest round date
January 2026
Industry
Biotech
Headquarters
Brisbane, Australia
Notable investors
Ally Bridge Group, Alpha Wave, Bain Capital Life Sciences, Fidelity Management & Research, T. Rowe Price, Qatar Investment Authority, Eli Lilly, Sanofi Ventures
Frequently asked about AdvanCell funding
How much has AdvanCell raised?
AdvanCell has raised $440M in total disclosed funding across the rounds on record.
Who has invested in AdvanCell?
Ally Bridge Group, Alpha Wave, Bain Capital Life Sciences, Fidelity Management & Research, T. Rowe Price, Qatar Investment Authority are named among the investors backing AdvanCell.
What was the latest AdvanCell funding round?
The most recent disclosed round is a Series D, announced in January 2026.
Where is AdvanCell based?
AdvanCell is based in Brisbane, Australia.
What sector does AdvanCell operate in?
AdvanCell is tracked under Biotech from Brisbane, Australia, with $440M in disclosed funding.
When did AdvanCell last raise?
The last disclosed AdvanCell round closed in January 2026 at Series D.
Round data for AdvanCell is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies in Brisbane and backer lists below.
